{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:32:35Z","timestamp":1794533555144,"version":"4.9.1"},"reference-count":73,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"crossref","award":["Answer Fund"],"award-info":[{"award-number":["Answer Fund"]}],"id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["3 R01 CA192844-04S1"],"award-info":[{"award-number":["3 R01 CA192844-04S1"]}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"crossref","award":["ASH Scholar Award"],"award-info":[{"award-number":["ASH Scholar Award"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["1K22CA266739"],"award-info":[{"award-number":["1K22CA266739"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanisms are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted chromatin-bound IKZF1, but eviction of P300 and BRD4 coactivators only occurred in IMiD-sensitive cells. IKZF1-bound enhancers overlapped other transcription factor binding motifs, including ETV4. Chromatin immunoprecipitation sequencing showed that ETV4 bound to the same enhancers as IKZF1, and ETV4 CRISPR\/Cas9-mediated ablation resulted in sensitization of IMiD-resistant MM. ETV4 expression is associated with IMiD resistance in cell lines, poor prognosis in patients, and is upregulated at relapse. These data indicate that ETV4 alleviates IKZF1 and IKZF3 dependency in MM by maintaining oncogenic enhancer activity and identify transcriptional plasticity as a previously unrecognized mechanism of IMiD resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by maintaining MYC and other oncogenes. These data implicate transcription factor redundancy as a previously unrecognized mode of IMiD resistance in MM.<\/jats:p>\n                    <jats:p>See related article by Welsh, Barwick, et al., p. 34.<\/jats:p>\n                    <jats:p>See related commentary by Yun and Cleveland, p. 5.<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 4<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0061","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:48:43Z","timestamp":1699364923000},"page":"56-73","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["ETV4-Dependent Transcriptional Plasticity Maintains\n                    <i>MYC<\/i>\n                    Expression and Results in IMiD Resistance in Multiple Myeloma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-3647","authenticated-orcid":false,"given":"Paola","family":"Neri","sequence":"first","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1390-6699","authenticated-orcid":false,"given":"David","family":"Jung","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1198-6341","authenticated-orcid":false,"given":"Jonathan C.","family":"Patton","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2406-1122","authenticated-orcid":false,"given":"Ranjan","family":"Maity","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3840-3396","authenticated-orcid":false,"given":"Ines","family":"Tagoug","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-140X","authenticated-orcid":false,"given":"Caleb K.","family":"Stein","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-2162","authenticated-orcid":false,"given":"Remi","family":"Tilmont","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-7127","authenticated-orcid":false,"given":"Noemie","family":"Leblay","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-6843","authenticated-orcid":false,"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-0848","authenticated-orcid":false,"given":"Holly","family":"Lee","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-2162","authenticated-orcid":false,"given":"Seth J.","family":"Welsh","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-2027","authenticated-orcid":false,"given":"Daniel L.","family":"Riggs","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-637X","authenticated-orcid":false,"given":"Nicholas","family":"Stong","sequence":"additional","affiliation":[{"name":"4Translational Medicine, Bristol Myers Squibb, Summit, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1524-6156","authenticated-orcid":false,"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[{"name":"5Predictive Sciences, Bristol Myers Squibb, Summit, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-1706","authenticated-orcid":false,"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[{"name":"6Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-7399","authenticated-orcid":false,"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[{"name":"7Translational Genomics Research Institute, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, \u00adCanada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"2024012514550321700_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"2024012514550321700_bib2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"2024012514550321700_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"2024012514550321700_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2024012514550321700_bib5","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2024012514550321700_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"2024012514550321700_bib7","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"2024012514550321700_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"2024012514550321700_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"2024012514550321700_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.1439790","article-title":"Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment","volume":"258","author":"Georgopoulos","year":"1992","journal-title":"Science"},{"key":"2024012514550321700_bib11","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/emboj\/16.8.2004","article-title":"Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation","volume":"16","author":"Morgan","year":"1997","journal-title":"EMBO J"},{"key":"2024012514550321700_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1074-7613(00)80637-8","article-title":"Aiolos regulates B cell activation and maturation to effector state","volume":"9","author":"Wang","year":"1998","journal-title":"Immunity"},{"key":"2024012514550321700_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1126\/science.6306772","article-title":"Transcriptional enhancer elements in the mouse immunoglobulin heavy chain locus","volume":"221","author":"Mercola","year":"1983","journal-title":"Science"},{"key":"2024012514550321700_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0092-8674(83)90014-4","article-title":"A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene","volume":"33","author":"Gillies","year":"1983","journal-title":"Cell"},{"key":"2024012514550321700_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(83)90015-6","article-title":"A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes","volume":"33","author":"Banerji","year":"1983","journal-title":"Cell"},{"key":"2024012514550321700_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12975","article-title":"Epigenetic gene regulation in plasma cells","volume":"303","author":"Patterson","year":"2021","journal-title":"Immunol Rev"},{"key":"2024012514550321700_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2024012514550321700_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2024012514550321700_bib19","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"key":"2024012514550321700_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-021-00421-7","article-title":"Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma","volume":"11","author":"Jia","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024012514550321700_bib21","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-20-2931","article-title":"Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma","volume":"27","author":"Barwick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024012514550321700_bib22","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1101\/gad.283762.116","article-title":"Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia","volume":"30","author":"Hu","year":"2016","journal-title":"Genes Dev"},{"key":"2024012514550321700_bib23","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012514550321700_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2024012514550321700_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"2024012514550321700_bib26","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"2024012514550321700_bib27","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"2024012514550321700_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Nat Acad Sci U S A"},{"key":"2024012514550321700_bib29","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"2024012514550321700_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"2024012514550321700_bib31","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2024012514550321700_bib32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"2024012514550321700_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"key":"2024012514550321700_bib34","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024012514550321700_bib35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"2024012514550321700_bib36","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"2024012514550321700_bib37","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"2024012514550321700_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"2024012514550321700_bib39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2024012514550321700_bib40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"De Matos Simoes","year":"2023","journal-title":"Nat Cancer"},{"key":"2024012514550321700_bib41","doi-asserted-by":"crossref","first-page":"568915","DOI":"10.1038\/s41467-019-09982-5","article-title":"CUT&Tag for efficient epigenomic profiling of small samples and single cells","volume":"10","author":"Kaya-Okur","year":"2019","journal-title":"Nat Commun"},{"key":"2024012514550321700_bib42","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"key":"2024012514550321700_bib43","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"2024012514550321700_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"2024012514550321700_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"2024012514550321700_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"2024012514550321700_bib47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"2024012514550321700_bib48","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol;"},{"key":"2024012514550321700_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2024012514550321700_bib50","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","article-title":"Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition","volume":"81","author":"Hogg","year":"2021","journal-title":"Mol Cell"},{"key":"2024012514550321700_bib51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem Biol"},{"key":"2024012514550321700_bib52","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"2024012514550321700_bib53","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-014-2063-7","article-title":"Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma","volume":"93","author":"Huang","year":"2014","journal-title":"Ann Hematol"},{"key":"2024012514550321700_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"key":"2024012514550321700_bib55","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"key":"2024012514550321700_bib56","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"key":"2024012514550321700_bib57","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"2024012514550321700_bib58","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","volume":"48","author":"Corces","year":"2016","journal-title":"Nat Genet"},{"key":"2024012514550321700_bib59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"2024012514550321700_bib60","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2024012514550321700_bib61","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/nprot.2012.101","article-title":"Identifying ChIP-seq enrichment using MACS","volume":"7","author":"Feng","year":"2012","journal-title":"Nat Protoc"},{"key":"2024012514550321700_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45839-z","article-title":"The ENCODE blacklist: Identification of problematic regions of the genome","volume":"9","author":"Amemiya","year":"2019","journal-title":"Sci Rep"},{"key":"2024012514550321700_bib63","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41467-018-04234-4","article-title":"B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation","volume":"9","author":"Barwick","year":"2018","journal-title":"Nat Commun"},{"key":"2024012514550321700_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2024012514550321700_bib65","doi-asserted-by":"crossref","first-page":"91D","DOI":"10.1093\/nar\/gkh012","article-title":"JASPAR: an open-access database for eukaryotic transcription factor binding profiles","volume":"32","author":"Sandelin","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2024012514550321700_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024012514550321700_bib67","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"2024012514550321700_bib68","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"2024012514550321700_bib69","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Nat Acad Sci U S A"},{"key":"2024012514550321700_bib70","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol"},{"key":"2024012514550321700_bib71","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/bioinformatics\/btp328","article-title":"rtracklayer: an R package for interfacing with genome browsers","volume":"25","author":"Lawrence","year":"2009","journal-title":"Bioinformatics"},{"key":"2024012514550321700_bib72","doi-asserted-by":"crossref","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","article-title":"DELLY: structural variant discovery by integrated paired-end and split-read analysis","volume":"28","author":"Rausch","year":"2012","journal-title":"Bioinformatics"},{"key":"2024012514550321700_bib73","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0061\/3380850\/bcd-23-0061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0061\/3389451\/bcd-23-0061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/56\/3408492\/56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/56\/3408492\/56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:58:44Z","timestamp":1706176724000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/1\/56\/732333\/ETV4-Dependent-Transcriptional-Plasticity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,6]]},"published-print":{"date-parts":[[2024,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0061","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.24958716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958704","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958719.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958716.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958695","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062088","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958689.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958689","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062109.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062094","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958698.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062100.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062103","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958692.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958695.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062091.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062085.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062103.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062088.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062106.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062109","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062091","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062112.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958707","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958713.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062097","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062085","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958698","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062097.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958707.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958701","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958713","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062106","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062094.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958704.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958692","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958701.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062100","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062112","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7014120.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7014120.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7014120","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}